UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy.

Douglas, Kenneth W and Gilleece, Maria and Hayden, Patrick and Hunter, Hannah and Johnson, Peter R E and Kallmeyer, Charlotte and Malladi, Ram K and Paneesha, Shankara and Pawson, Rachel and Quinn, Michael and Raj, Kavita and Richardson, Deborah and Robinson, Stephen and Russell, Nigel and Snowden, John and Sureda, Anna and Tholouli, Eleni and Thomson, Kirsty and Watts, Mike and Wilson, Keith M (2017) UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy. Journal of clinical apheresis. ISSN 1098-1101. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

Full text not available from this repository.

Abstract

Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail. Pre-emptive use has the advantage that it avoids the need to re-schedule the transplant procedure, with its attendant inconvenience, quality-of-life issues for the patient and cost of additional admissions to the transplant unit. UK experience from 2 major centers suggests that pre-emptive plerixafor is associated with an incremental drug cost of less than £2000 when averaged over all patients undergoing peripheral blood stem cell (PBSC) transplant. A CD34+ cell count of <15 µl(-1) at the time of recovery after chemomobilization or after four days of G-CSF treatment, or an apheresis yield of <1 × 10(6) CD34+ cells/kg on the first day of apheresis, could be used to predict the need for pre-emptive plerixafor.

Item Type:	Article
Additional Information:	This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects:	QZ Pathology. Oncology WH Haemic and lymphatic systems. Haematology
Divisions:	Planned IP Care > Oncology and Clinical Haematology
Related URLs:	https://www.ncbi.nlm.nih.gov/pubmed/?ter...
Depositing User:	Mrs Caroline Tranter
Date Deposited:	23 Jun 2017 15:25
Last Modified:	23 Jun 2017 15:25
URI:	http://www.repository.heartofengland.nhs.uk/id/eprint/1424

Actions (login required)

View Item